These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

243 related articles for article (PubMed ID: 12769625)

  • 1. Muscarinic receptors as a target for drugs treating schizophrenia.
    Bymaster FP; Felder C; Ahmed S; McKinzie D
    Curr Drug Targets CNS Neurol Disord; 2002 Apr; 1(2):163-81. PubMed ID: 12769625
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Potential role of muscarinic receptors in schizophrenia.
    Bymaster FP; Shannon HE; Rasmussen K; DeLapp NW; Ward JS; Calligaro DO; Mitch CH; Whitesitt C; Ludvigsen TS; Sheardown M; Swedberg M; Rasmussen T; Olesen PH; Jeppesen L; Sauerberg P; Fink-Jensen A
    Life Sci; 1999; 64(6-7):527-34. PubMed ID: 10069519
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Xanomeline and the antipsychotic potential of muscarinic receptor subtype selective agonists.
    Mirza NR; Peters D; Sparks RG
    CNS Drug Rev; 2003; 9(2):159-86. PubMed ID: 12847557
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Xanomeline, an M(1)/M(4) preferring muscarinic cholinergic receptor agonist, produces antipsychotic-like activity in rats and mice.
    Shannon HE; Rasmussen K; Bymaster FP; Hart JC; Peters SC; Swedberg MD; Jeppesen L; Sheardown MJ; Sauerberg P; Fink-Jensen A
    Schizophr Res; 2000 May; 42(3):249-59. PubMed ID: 10785583
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Muscarinic mechanisms in psychotic disorders.
    McKinzie DL; Bymaster FP
    Handb Exp Pharmacol; 2012; (213):233-65. PubMed ID: 23027418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The M₁/M₄ preferring agonist xanomeline reverses amphetamine-, MK801- and scopolamine-induced abnormalities of latent inhibition: putative efficacy against positive, negative and cognitive symptoms in schizophrenia.
    Barak S; Weiner I
    Int J Neuropsychopharmacol; 2011 Oct; 14(9):1233-46. PubMed ID: 21211109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Novel pharmacological approaches to the treatment of schizophrenia.
    Fink-Jensen A
    Dan Med Bull; 2000 Jun; 47(3):151-67. PubMed ID: 10913983
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Decreased prepulse inhibition and increased sensitivity to muscarinic, but not dopaminergic drugs in M5 muscarinic acetylcholine receptor knockout mice.
    Thomsen M; Wörtwein G; Fink-Jensen A; Woldbye DP; Wess J; Caine SB
    Psychopharmacology (Berl); 2007 May; 192(1):97-110. PubMed ID: 17310388
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Unexpected antipsychotic-like activity with the muscarinic receptor ligand (5R,6R)6-(3-propylthio-1,2,5-thiadiazol-4-yl)-1-azabicyclo[3.2.1]octane .
    Bymaster FP; Shannon HE; Rasmussen K; Delapp NW; Mitch CH; Ward JS; Calligaro DO; Ludvigsen TS; Sheardown MJ; Olesen PH; Swedberg MD; Sauerberg P; Fink-Jensen A
    Eur J Pharmacol; 1998 Sep; 356(2-3):109-19. PubMed ID: 9774240
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Activation of midbrain presumed dopaminergic neurones by muscarinic cholinergic receptors: an in vivo electrophysiological study in the rat.
    Gronier B; Rasmussen K
    Br J Pharmacol; 1998 Jun; 124(3):455-64. PubMed ID: 9647468
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Involvement of a subpopulation of neuronal M4 muscarinic acetylcholine receptors in the antipsychotic-like effects of the M1/M4 preferring muscarinic receptor agonist xanomeline.
    Dencker D; Wörtwein G; Weikop P; Jeon J; Thomsen M; Sager TN; Mørk A; Woldbye DP; Wess J; Fink-Jensen A
    J Neurosci; 2011 Apr; 31(16):5905-8. PubMed ID: 21508215
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The muscarinic M1/M4 receptor agonist xanomeline exhibits antipsychotic-like activity in Cebus apella monkeys.
    Andersen MB; Fink-Jensen A; Peacock L; Gerlach J; Bymaster F; Lundbaek JA; Werge T
    Neuropsychopharmacology; 2003 Jun; 28(6):1168-75. PubMed ID: 12700711
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effect of muscarinic receptor agonists xanomeline and sabcomeline on acetylcholine and dopamine efflux in the rat brain; comparison with effects of 4-[3-(4-butylpiperidin-1-yl)-propyl]-7-fluoro-4H-benzo[1,4]oxazin-3-one (AC260584) and N-desmethylclozapine.
    Li Z; Snigdha S; Roseman AS; Dai J; Meltzer HY
    Eur J Pharmacol; 2008 Oct; 596(1-3):89-97. PubMed ID: 18771666
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Muscarinic Acetylcholine Receptor Agonists as Novel Treatments for Schizophrenia.
    Paul SM; Yohn SE; Popiolek M; Miller AC; Felder CC
    Am J Psychiatry; 2022 Sep; 179(9):611-627. PubMed ID: 35758639
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Selective activation of muscarinic acetylcholine receptors for the treatment of schizophrenia.
    Dean B
    Curr Pharm Biotechnol; 2012 Jun; 13(8):1563-71. PubMed ID: 22283751
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The neurobiology of cognition in schizophrenia.
    Tamminga CA
    J Clin Psychiatry; 2006; 67 Suppl 9():9-13; discussion 36-42. PubMed ID: 16965183
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Targeting muscarinic receptors to treat schizophrenia.
    Foster DJ; Bryant ZK; Conn PJ
    Behav Brain Res; 2021 May; 405():113201. PubMed ID: 33647377
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Muscarinic receptor agonists, like dopamine receptor antagonist antipsychotics, inhibit conditioned avoidance response in rats.
    Shannon HE; Hart JC; Bymaster FP; Calligaro DO; DeLapp NW; Mitch CH; Ward JS; Fink-Jensen A; Sauerberg P; Jeppesen L; Sheardown MJ; Swedberg MD
    J Pharmacol Exp Ther; 1999 Aug; 290(2):901-7. PubMed ID: 10411607
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dysfunctional brain dopamine systems induced by psychotomimetic NMDA-receptor antagonists and the effects of antipsychotic drugs.
    Svensson TH
    Brain Res Brain Res Rev; 2000 Mar; 31(2-3):320-9. PubMed ID: 10719159
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Simultaneous activation of muscarinic and GABA
    Cieślik P; Woźniak M; Tokarski K; Kusek M; Pilc A; Płoska A; Radulska A; Pelikant-Małecka I; Żołnowska B; Sławiński J; Kalinowski L; Wierońska JM
    Behav Brain Res; 2019 Feb; 359():671-685. PubMed ID: 30267715
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 13.